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Abstract Dialytic intervention for infants and children
with acute kidney injury (AKI) can take many forms.
Whether patients are treated by intermittent hemodialysis,
peritoneal dialysis or continuous renal replacement therapy
depends on specific patient characteristics. Modality choice
is also determined by a variety of factors, including
provider preference, available institutional resources, dia-
lytic goals and the specific advantages or disadvantages of
each modality. Our approach to AKI has benefited from the
derivation and generally accepted defining criteria put forth
by the Acute Dialysis Quality Initiative (ADQI) group.
These are known as the risk, injury, failure, loss, and end-
stage renal disease (RIFLE) criteria. A modified pediatrics
RIFLE (pRIFLE) criteria has recently been validated.
Common defining criteria will allow comparative investi-
gation into therapeutic benefits of different dialytic inter-
ventions. While this is an extremely important development
in our approach to AKI, several fundamental questions
remain. Of these, arguably, the most important are “When
and what type of dialytic modality should be used in the
treatment of pediatric AKI?” This review will provide an
overview of the limited data with the aim of providing
objective guidelines regarding modality choice for pediatric
AKI. Comparisons in terms of cost, availability, safety and
target group will be reviewed.
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Introduction
The epidemiology of pediatric acute kidney injury (AKI),
the treatment approaches, identification and validation of
objective variables and technological refinements in mon-
itoring equipment, access, and renal replacement therapy
(RRT) machinery have all changed over the past decade.
Overall, AKI remains a significant contributor to the
morbidity and mortality of critically ill infants and children,
especially those with multi-system organ failure [1]. There
have been at least 30 different definitions of AKI reported
in the literature [2]. To date, it has generally been accepted
that AKI is characterized by the failure of the kidneys to
regulate electrolyte, acid–base and fluid homeostasis
adequately, with a concomitant reduction in glomerular
filtration rate [3, 4]. In practical terms this may be
demonstrated in the pediatric patient by an increase in
nitrogenous waste products [blood urea nitrogen (BUN)],
an associated increase in serum creatinine (>50% above
baseline level) and, in most cases, a concomitant reduction
in urine output (less than 0.5–1 ml/kg per hour) [3–5].
These varied definitions have resulted in our inability to
assess data sets comparatively between studies, making
meta-analysis extremely difficult. This also has significant-
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RRT options in like patient groups. Controversy remains as
to when specifically RRT is indicated in terms of creatinine/
BUN rise, fluid overload, associated organ failure, type of
RRT to employ, which patient population will benefit most
(if at all) from which RRT therapy and how early should
therapy be initiated.
So that such fundamental questions can be addressed, a
commonly accepted and utilized AKI definition is required.
The Acute Dialysis Quality Initiative (ADQI) was formed
in early 2000 and was composed of nephrologists and
intensivists, including pediatric representation (www.
ADQI.net). The group objectively scrutinized available
AKI data and classified it as to scientific merit. From these
consensus meetings, criteria for AKI were defined and
validated. These criteria are known as the risk, injury,
failure, loss, and end-stage renal disease, or RIFLE, criteria
[2]. A recent pediatric study has validated a modified form
of these criteria, the “pRIFLE” [6].
Epidemiologic distribution of pediatric AKI varies
according to the type of institution reporting results. Those
units containing high surgical and trauma volumes, as well
as concentrated sub-specialty services, may garner a greater
number of pediatric patients with AKI than the smaller or
less developed centers [7–11]. Recently, Hui-Stickle et al.
noted the dramatic broadening of pediatric AKI epidemiology
[12]. Prior to the 1990s, the most prevalent causes cited were
hemolytic uremic syndrome, other primary renal causes,
sepsis, and burns [13–18]. Now, the most common causes in
developed countries may involve multiple system diseases or
failures, including congenital heart disease, acute tubular
necrosis, nephrotoxic medications, and sepsis [12]. In
developing countries hemolytic uremic syndrome (HUS)
continues to be reported as one of the primary causes of
pediatric AKI [19].
In parallel to the changes in AKI epidemiology, there
have been dramatic changes to our approaches to RRT in
pediatric AKI. The conservative management goals of
pediatric AKI include symptomatic measures such as
control of fluid balance, dietary and blood pressure
management, and improvement of survival time. In the
setting of AKI, disturbed fluid or metabolic balance often
necessitates the initiation of RRT [14, 20, 21]. Historically,
the reported mortality rates for children requiring dialysis
ranged anywhere from 35% to 73% [7–10, 22]. However,
more recent pediatric RRT demographic data has stratified
diagnoses and clarified outcome numbers, suggesting that
refinement of variables, use of severity of illness scores,
and earlier intervention are, for the first time, providing
improved care with improved outcomes [23].
A great number of modalities is currently available for
the provision of RRT in the pediatric patient with AKI.
Intermittent hemodialysis (IHD), peritoneal dialysis (PD),
and continuous renal replacement therapies (CRRT) such as
continuous venovenous hemodialysis (CVVHD) (predom-
inantly diffusive clearance), continuous venovenous hemo-
filtration (CVVH) (convective clearance), or continuous
venovenous hemodiafiltration (CVVHDF) (both convective
and diffusive clearance), may be employed to provide
enhanced solute clearance and ultrafiltration [3, 24, 25].
While temporary IHD is the most efficient modality for
fluid and metabolic control, it is often not feasible for our
smallest and/or sickest patients in the pediatric intensive
care unit (ICU), due to large extracorporeal circuit volumes
and the inability of patients to tolerate rapid fluid shifts. In
such settings the alternative use of PD or CRRT has
become the mainstay of RRT. In general, PD has long been
preferred and utilized as a form of continuous therapy in the
setting of AKI in pediatrics [26, 27]. The continued
improvements and refinements of CRRT technologies has
allowed these systems to be employed in our smallest
patients with more-complicated and unstable disease,
especially in resource-rich countries [28–33]. As more and
more providers of pediatric care are equipped with the
ability to provide CRRT, it is fast becoming the standard of
care in the ICU setting. Warady and Bunchman [34] noted
that, in just a 4-year period (1995–1999), the preferred
modality for the treatment of pediatric AKI had changed
from PD to CRRT, with a 100% (18 to 36) increase in the
number of centers reporting CRRT as the primary initial
modality of treatment. Currently, it is unclear which
patients with AKI require which specific therapy, and some
patients may benefit from the provision of PD rather than
IHD or CRRT in specific circumstances. Indeed, individual
practices or clinical settings may not have the availability of
a variety of modalities. The choice of PD, IHD or CRRT is
dependent on a variety of factors, both from a patient
perspective and from a center perspective. The following
will review the current state of literature comparing the use
of PD, IHD and CRRT for the treatment of AKI in
pediatrics, outlining the advantages and disadvantages in
relationship to efficiency, complications, complexity, disease
process and outcomes.
Modality choice
The choice of an appropriate modality for AKI depends on
the clinical status of the patient as well as the dialytic
indication. Clinically, several important patient conditions
require attention. Initial patient assessment should focus on
whether multiple organ systems are involved and to what
extent. A patient with AKI solely, will predictably have a
better potential outcome than those with multi-system
failure [23, 35]. If AKI is the only morbidity associated
with the patient, then it is important that quantification of
urine output (if present) be acknowledged. This will help
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load. Classically defined indicators for RRT initiation in the
setting of AKI are extrapolations of those we have
commonly used for end-stage renal disease (ESRD) and
include: metabolic/electrolyte imbalance, uremia with
bleeding and/or encephalopathy, hypervolemia with pulmo-
nary edema/respiratory failure, intoxications, inborn errors
of metabolism (IEM), and nutritional support. While these
may be recognized indicators, to date there has been no
adequate definition of what “timing of initiation” means.
The decision to initiate RRT may be affected by strongly
held physician beliefs (in terms of indications), patient
characteristics (including age/size, illness acuity, and co-
morbidities) and organizational characteristics (including
resource availability, type of institution, type of ICU, type
of provider, and perceived cost of therapy). All these factors
will ultimately determine the appropriateness and availabil-
ity of modality choice.
Indications
Specific indications for RRT typically include the need for
ultrafiltration (i.e. fluid removal), either for symptomatic
volume overload, or to make space for nutrition, medica-
tions, and blood product support and/or solute removal (i.e.
urea, potassium), either for uremia or for removal of a
dialyzable toxin. In addition to these clinical variables, the
use of specific modalities in terms of need for nutritional
support to aid in patient recovery from AKI or its
underlying cause [36–38] must be considered. The rapid
removal of solute (urea) and correction of electrolyte
abnormalities (particularly elevated levels of potassium)
are of extreme importance in the setting of AKI. While PD,
IHD and CRRT can rapidly correct hyperkalemia and
uremia, IHD and CRRT provide greater clearance of higher
molecular weight solutes than PD. The rapidity of solute
generation and its particular urgency for removal, as in
tumor lysis syndrome, IEM, hyperammonemia, symptom-
atic hyperkalemia, or ingestion of dialyzable toxins, require
IHD or CRRT rather than PD, whereas mild uremia can be
treated with any of the modalities [39–43]. Urgent fluid
removal required in patients with pulmonary edema and
difficulty in ventilating may only be achieved by IHD or
CRRT. Mild volume overload can be treated with any
modality. For example, a hemodynamically unstable patient
with overwhelming sepsis, fluid overload, respiratory
compromise, pressor requirements and renal involvement
may necessitate initiation of CRRT for close fluid status
control, whereas a post-operative cardiac patient with
minimal fluid overload and hemodynamic instability may
be better served by PD. The physical characteristics of the
type of solute to be removed (i.e. molecular size,
percentage of protein binding) may determine the need for
IHD vs PD vs CRRT (CVVH vs CVVHD). The metabolic
status of the patient may also reflect the type of dialytic
solution required.
Patient characteristics/contraindications
The physical condition of a patient in terms of underlying
disease process, size, previous surgical procedures and
overall stability will often dictate choice of modality.
Contraindications to PD may include diaphragmatic hernia,
recent intra-abdominal surgery, intra-abdominal sepsis, lack
of an adequate peritoneal surface, or intra-abdominal
malignancy. Also, in AKI secondary to HUS, gut involve-
ment may be severe enough to preclude PD, as may
necrotizing enterocolitis in a neonate. Severe hypotension
may prohibit the use of IHD. A patient’s size may prevent
successful vascular access or even temporary PD. Indeed,
in our smallest neonates, vascular access may not be
achievable with double lumen catheters in the neck or
groin, and single lumen 5 Fr. catheters may need to be
placed in the umbilical vessels. In the same neonatal patient
even temporary PD may be impossible when automated
machinery is used, due to tubing “dead space”. Such
considerations must be taken into account in determining
the feasibility of dialysis delivery in our smallest patients.
The presence of a coagulopathy may impact on perfor-
mance of IHD or CRRT, or the ability to establish vascular
access for either modality.
Organizational characteristics
In some geographical locations resources are the limiting
factor. PD may have to suffice if no other form of RRT is
available. For example, the literature clearly supports IHD
and CRRT over PD in the treatment of IEM; however, even
PD may provide clearance and should be utilized when no
other options exist. Along with availability, the ability for
IHD or CRRT to be initiated rapidly may be an issue,
depending on staffing and expertise.
The overall approach to the uniform clinical assessment
is to determine what the major goal of dialytic therapy is.
Does the patient need only solute clearance? If so, what
solute (molecular weight), and how quickly? Does he or she
need primarily ultrafiltration? If so, how quickly must fluid
removal be achieved and what is the hemodynamic
stability? What are the resources available? What limiting
factors are present in terms of the patient’s condition? All of
these considerations must be taken into account if we are to
deliver appropriate therapy in the right context.
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Historically, PD has been the primary RRT modality
employed in pediatric care. Experientially, most clinicians
have a relatively greater comfort level with employing this
therapy, and it has been effective for the management of
childhood AKI [7–10, 44–48]. Indeed, recent reports from
Nigeria, India and Brazil have demonstrated its continued
efficacy in the treatment of pediatric AKI [19, 49, 50]. PD
offers a variety of advantages in the acutely ill pediatric
population with AKI (see Table 1).
Technical aspects
From a technical aspect, access can be relatively quickly
and safely obtained, even in hemodynamically unstable
patients and those with a coagulopathy. PD is superior in its
requirement for less clinical expertise, fewer equipment
resources, and cost. This dialysis modality is critical to AKI
in facilities where pediatric IHD and CRRT are not
available, as is the case in more rural areas and most
developing countries [19, 50]. PD does not require vascular
access, thereby allowing critically ill patients to be dialyzed
with preservation of vasculature for future procedural
necessities. Access in the form of classically surgically
placed Tenckhoff catheters, or short-term PD or adapted PD
catheters placed at the bedside percutaneously [51, 52]i n
patients unable to tolerate surgical placement, allow the
rapid institution of therapy. This also potentially eliminates
the need for an ICU environment for patients whose
condition is stable. This technique is usually well tolerated
in our smallest patients. In the USA, the neonatal 5 Fr.
temporary “stab” catheter (Cook Medical Incorporated,
Bloomington, IN, USA), is no longer available, but the
Table 1 Comparison of the advantages and disadvantages of continuous renal replacement therapies (CRRT) and peritoneal dialysis (PD) and
intermittent hemodialysis (IHD). IPD intermittent peritoneal dialysis, VP ventriculoperitoneal, ICU intensive care unit
Variable CRRT PD IHD
Continuous therapy Yes Yes No
Hemodynamic stability Yes Yes No
Fluid balance achieved Yes, pump controlled Yes/no, variable Yes, intermittent
Easy to perform No Yes No
Metabolic control Yes Yes Yes, intermittent
Optimal nutrition Yes No No
Continuous toxin removal Yes No/yes, depends on the nature
of the toxin—larger molecules
not well cleared
No
Anticoagulation Yes, requires continuous
anticoagulation
No, anticoagulation not required Yes/no, intermittent
anticoagulation
Rapid poison removal Yes/no, depending on
patient size and dose
No Yes
Stable intracranial pressure Yes Yes/no, less predictable than CRRT Yes/no, less predictable
than CRRT
ICU nursing support Yes, high level of support Yes/no, moderate level of support
(if frequent, manual cycling can
be labor intensive)
No, low level of support
Dialysis nursing support Yes/no, institution
dependent
Yes/no, institution dependent Yes
Patient mobility No Yes, if IPD used No
Cost High Low/moderate. Increases with
increased dialysis fluid used
High/moderate
Vascular access required Yes No Yes
Recent abdominal surgery
a Yes No Yes
VP shunt Yes Yes/no, relative contraindication Yes
Prune belly syndrome Yes Yes/no, relative contraindication Yes
Ultrafiltration control Yes Yes/no, variable Yes, intermittent
PD catheter leakage No Yes No
Infection potential Yes Yes Yes
Use in AKI-associated
inborn errors of metabolism
Yes No Yes
Use in AKI-associated ingestions Yes No Yes
aOmphalocele, gastroschisis, frequent or extensive abdominal surgery
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neonates without difficulty. Drawbacks for the use of
short-term PD “stab” catheters include the risk of leakage,
infection, and the initiation with relatively small volumes
of dialysate (usually 10 ml/kg) limiting adequate clearance.
Complications can also include bladder and bowel
perforation, along with bleeding issues related to the
procedure. If possible, surgical placement is therefore
advised [46, 53, 54].
If very low-volume, automated, PD cycler systems are
not available, PD can be performed manually in infants.
Institution of continuous PD may be easily accomplished
with manual exchange systems [the Dialy-Nate system/
Gesco Dialy-nate (Utah Medical Products, Midvale, Utah,
USA) or the PD-Paed system (Fresenius Medical Care, Bad
Homburg, Germany)] for infants. These manual exchange
systems are not inexpensive, but they are readily available
worldwide, unlike IHD and CRRT equipment. Dialysate is
available worldwide and in circumstances where avoidance
of lactate-based solutions is in the patient’s best interest
(i.e. patients with hepatic dysfunction or lactic acidosis);
commercially available pure bicarbonate and bicarbonate/
lactate solutions are available outside the USA. Alternately,
“custom-made” bicarbonate solutions can be prepared by
hospital pharmacies at an additional cost [55, 56]. The
dextrose used in PD dialysate can provide an extra source
of carbohydrate nutrition and calories [57, 58]; however,
this can also lead to hyperglycemia [59], necessitating
insulin correction. Supplementation with sodium (if com-
mercial preparations are used) and amino acids may be
required, due to increased clearance in the setting of AKI.
Efficiency and therapeutic advantages/disadvantages
Therapeutically, PD provides gradual and continuous solute
clearance and ultrafiltration, thereby mimicking renal
function to some extent. This property is a major
contributing factor to treatment of pediatric patients with
cardiovascular instability with PD. Several retrospective
analyses have demonstrated that PD can be successfully
performed in pediatric patients with hemodynamic instabil-
ity and multi-system organ failure requiring vasopressor
support [48, 49]. However, for these patients, the efficiency
of PD may be suboptimal, and vigilance on the part of the
clinician is required. Close monitoring is also required for
patients with pre-load-dependent cardiac physiology. The
condition of these individuals will most likely be unstable
with filling and draining [35, 48], and they may require
tidal PD prescriptions or an alternative modality. Indeed,
the beneficial aspects of PD (slow solute clearance and
ultrafiltration) also become one of its disadvantages for
several patient populations, particularly those with severe
fluid overload or severe lactic acidosis requiring precise
fluid balance and controlled ultrafiltration that can only be
attained with IHD or CRRT.
PD has limitations for certain populations. Those with
pulmonary compromise may have a worsening of their
symptoms due to increased abdominal dialysate volumes,
thereby preventing full diaphragmatic excursion [60, 61].
Patients with ventriculoperitoneal shunts or prune belly
syndrome have been successfully dialyzed with PD but do
present increased potential complications. Finally, patients
that have undergone abdominal surgery may not be
amenable to utilizing this therapy, and, in patients with
diaphragmatic defects, the use of PD is contraindicated.
The process of PD itself can cause significant losses in
immunoglobulins, increasing the risk of infections in these
patients. Peritonitis can lead to further increased dialysate
protein loss, nutritional compromise, loss of ultrafiltration
capacity, and permanent damage to the peritoneal mem-
brane [62].
Mechanical complications associated with PD include
leaks, hernias and catheter obstruction. Dialysate leakage
may occur around the catheter or into the pleural space,
resulting in hydrothorax. Drainage problems seen with PD
are typically caused from catheter malfunctions in the form
of omentum and fibrin clot obstructions [48, 50]. The
potential for complications from infections must not be
overlooked, and the clinician must remain vigilant to the
possibility of peritonitis, particularly fungal peritonitis.
Manual PD can be labor intensive for the bedside nurse,
depending on frequency of cycles. Additionally, warming
of dialysate is difficult without the use of an automatic
cycler. In the critical-care setting, warming of PD solution
is often difficult and overlooked, yet it is an important
component for maintaining hemodynamic stability and
improving effective solute clearance. Overall, the largest
expense associated with PD, outside of nursing, is the cost
of the dialysis fluid itself, regardless of whether it is
commercially prepared or “custom-made”.
The case for IHD in pediatric AKI
IHD has the clear advantage of rapid ultrafiltration or solute
removal when compared to PD or CRRT. In the hemody-
namically stable patient, no RRT modality is better suited
then IHD for the rapid clearance of an offending solute.
Along with PD, IHD can be performed outside of an ICU
setting. This method of therapy is particularly important in
ingestions, drug toxicity, tumor lysis syndrome and hyper-
ammonemia seen in the pediatric population [24, 41, 42]. In
such cases, CRRT can be utilized as step-down therapy to
prevent a rebound of certain toxins (i.e. ammonia, lithium)
once the initial IHD run has been completed [41, 43]. The
ability to adjust dialysate composition to treat various
electrolyte abnormalities (i.e. hyperkalemia, hypernatremia)
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CRRT [63].
Technical aspects
IHD requires technical expertise on the part of the
physician, nurse and technician for optimal support for the
wide range of pediatric patients, and, typically, it is
available in larger secondary and tertiary care hospitals.
Vascular access is, indeed, arguably the most important
component contributing to the satisfactory provision of this
therapy. In neonates the use of umbilical veins is an
important consideration for vascular access. Utilization of
neck veins, although limited by anatomy, may be preferable,
especially in infants weighing less than 5 kg. Such access
may allow for less recirculation and avoid the potential high
venous return pressures often associated with groin lines in
patients with high intra-abdominal pressures. While difficult
in the smallest infants, it is possible. A wide variety of
temporary vascular catheters are available for the pediatric
population [64]. The placement of vascular access can be
performed at the bedside by pediatric nephrologists or
intensivists, for short-term catheters, or in an operating room
by a surgeon or an interventional radiologist for permanent
tunneled catheters. Placement of temporary or permanent
vascular catheters for IHD can result in blood vessel stenosis
or thrombosis, along with air emboli or hemorrhage.
Depending on location or degree of difficulty involved in
the placement of short-term or permanent vascular catheters,
future access needs may be compromised. This issue
becomes of great importance for patients requiring long-
term access that progress from acute to chronic kidney
injury. If possible, subclavian catheter placement should be
avoided altogether, due to the very high incidence of stenosis
at the puncture site, which may render the formation of a
fistula impossible in the future. IHD can be utilized without
anticoagulation and does not require the extra central line
placement often needed for CRRT regional anticoagulation
with citrate.
Efficiency and therapeutic advantages/disadvantages
Because of the advantage of rapidity of fluid and/or solute
removal afforded by IHD, dialysis disequilibrium is a
potential complication seen in patients receiving this
therapy. Careful dosing, dialysate solution selection, judi-
cious use of mannitol, and monitoring are required to
prevent the dangerous osmolar shifts that can cause
complications of mental status changes and/or seizures
produced from the effects of cerebral edema [65]. Caution
must also be employed in the treatment of non-uremic
patients (e.g. inborn errors or intoxications). These patients
are at risk for developing severe hypophosphatemia, and
their levels of serum phosphate (PO4) must be carefully
monitored. Phosphate supplementation may be accom-
plished by addition to the dialysate bath (concentration
from 0.5 mmol/l to 1.5 mmol/l, as needed) or by the
administration of a separate phosphate infusion. These
potential complications reinforce the belief that IHD should
only be prescribed by nephrologists.
Additionally, as IHD will be able to achieve only a
certain amount of ultrafiltration in the time available for
treatment, fluid restriction usually will be required in the
oliguric or anuric AKI patient. This can limit the amount of
nutrition a patient will be able to receive over a 24-hour
period. Hypotensive patients will have a limited ability to
achieve appropriate fluid removal or even tolerate IHD. In
such cases PD or CRRT may provide a more gradual
ultrafiltration and be better tolerated. Filter membrane
biocompatibility (BCM) vs bioincompatibility (BICM)
appears to be an unresolved issue at this time. Certain
authors have suggested that only biocompatible membranes
be used in children with AKI [35], but a large Cochrane
review concluded that there is no demonstrable clinical
advantage to the use of BCM versus BICM in patients
(>18 years of age) with acute renal failure (ARF) who
require IHD [66].
The case for CRRT in pediatric AKI
CRRT is beginning to emerge from its infancy in terms of
when and how it should be used, which patient population
will most benefit, and which complications are most
commonly seen. Over the past 5 years several defining
principles of CRRT in infants and children have been
established. This work has been spear-headed by a
pediatric-based consortium comprising 13 US centers. This
group, known as the prospective pediatric CRRT (ppCRRT)
consortium, has redefined the demographics, outcomes, and
anticoagulation strategies, among other important variables,
in the treatment approach to pediatric AKI [23, 65–71].
Perhaps, one of the most important variables has been the
degree of fluid overload patients have when CRRT is
initiated, and its relationship to outcome. There are now
four published reports pointing out the importance that the
degree of fluid overload plays in the management of
pediatric AKI [71–74]. With these recent developments, it
appears as though changes in our treatment of the sickest
patients with CRRT has resulted in an improvement in
stratification of mortality rates compared to historical
outcomes [71, 75].
Technical aspects
Perhaps one of the greatest drawbacks of CRRT is its
complexity and expense compared with those of PD and, to
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CRRT has resulted in improved safety, but it has also
increased costs. The safe and proper provision of CRRT
requires specialized nursing education and pharmacy
support. Many institutions have compounded CRRT sol-
utions; however, with recent approval by the Food and
Drug Administration (FDA) of both commercially available
dialysate and filter replacement solutions, these support
requirements have substantially decreased [76–78].
There are also several unique requirements for CRRT
implementation in pediatrics. As with IHD, adequate
vascular access is required for CRRT. This technical aspect
is the most important consideration contributing to the
effectiveness of the therapy. Depending on the type of
anticoagulation used, an additional central line may be
required, as with regional citrate anticoagulation.
Historically, arteriovenous circuits were utilized; how-
ever, these have given way to commercially available
venovenous therapies, which are pump driven and provide
more predictable blood flow and, therefore, solute and
ultrafiltration rates. Despite the availability of smaller
circuits in some jurisdictions, the large extracorporeal
volume required for CRRT and IHD (particularly in
neonates) is a distinct disadvantage, necessitating blood
priming in patients weighing less than 10 kg. In these
settings, extracorporeal blood volume exceeds 10% of the
patient’s blood volume. This exposes the patient to obvious
risks associated with blood products and hemodynamic
instability related to the flow of blood out of the body.
Patients with multiple organ failure and hemodynamic
instability may not tolerate the rapid circulation of blood
through a CRRTcircuit, regardless of the patient’s size [79].
Additionally, depending on the types of hemofilters
utilized, hemodynamic instability may be observed with
CRRT due to bradykinin reactions, activation of comple-
ment-coagulation cascade-monocytes, neutrophil degranu-
lation and/or the release of reactive oxygen species [79, 80].
Some of the more significant technical disadvantages of
CRRT include the requirement for continuous anticoagula-
tion [69] and the clotting of circuits. While many easy
anticoagulation protocols are available, anticoagulation
comes with its own set of complications.
Efficiency and therapeutic advantages/disadvantages
CRRT has several distinct advantages over IHD and PD in
the treatment of patients with AKI. CRRT mimics the effect
of renal function with its continual ultrafiltration and solute
clearance [28, 30]. The predictability and efficiency of
ultrafiltration (UF) and solute removal make CRRT ideally
suited for the provision of RRT in hemodynamically
unstable patients. A particular advantage afforded by CRRT
(and IHD) is the ability for ultrafiltration to be separated
from solute removal, which allows more flexibility for
prescriptions to be tailored to the patient’s needs.
Minimal requirements for fluid restriction, due to
predictable and continual fluid removal while CRRT is
being performed, allow improved and adequate nutritional
delivery. The need for supplemental protein (as high as 3–
4 gm/kg per day) during CRRT must not be under-
estimated when this therapy is being used, as the sieving
coefficients of most amino acids are close to 1, and,
therefore, clearance is quite high and can result in a
nutritional deficit [81].
In the setting of AKI, CRRT can rapidly and predictably
restore homeostasis. Indeed, CRRT provides superior
uremia control compared to PD [49, 82] or even intermit-
tent daily hemodialysis [83, 84]. Alteration of dialysate or
filter replacement fluid is possible and can allow the
clinician to control electrolyte levels within a desired target
range; this is particularly important in the setting of
increased intracranial pressure, when higher sodium levels
may be required or when hyperosmolar states need to be
corrected [85]. Of course, due to potential compounding
errors, caution needs to be exercised when these alterations
are being made, and they should be done under careful
guidance of the clinician and pharmacist [77].
CRRT during AKI may have the additional benefit of
restoring immuno-homeostasis via removal of both pro-
inflammatory and anti-inflammatory molecules [86]. This
remains an area of active ongoing research.
CRRT vs PD and IHD outcomes
At the present time there have been no randomized clinical
trails comparing PD vs IHD vs CRRT for treatment of
children with AKI. To date only one randomized clinical
study of adults, comparing CRRT with PD, has been
published. This study was performed in a developing
country in terms of resources. Phu et al. [87] made an
open randomized comparison of PD vs CRRT in patients
with infection-related AKI. This 70-patient study (n=34 on
CRRT, n=36 on PD) found that for all their primary end
points (i.e. resolution of acidosis, reduction of creatinine),
CRRT was significantly superior to PD. Additionally, they
noted as secondary outcomes a significant survival differ-
ence between modalities, with CRRT resulting in an 85%
survival rate and PD associated with a 53% survival rate.
They also noted an overall cost reduction for patient care
with the use of CRRT, despite the higher technical costs of
this therapy. This was due to savings in duration of therapy
and overall reduction in total resource requirements per
patient. Their overwhelming conclusion was that CRRT
was superior to PD for the treatment of AKI associated with
infection. Their study has been criticized for the prescrip-
tion delivered with PD and other methodological issues
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the study provides the first randomized comparison of these
modalities. More recently, a pediatric-based retrospective
analysis [49] of 118 infants and children treated either with
PD (n=82) or CRRT (n=36) (followed by extended daily
dialysis in those showing signs of recovery) demonstrated
that, while there was no difference in mortality rates
between modalities, CRRT provided better fluid control
and was the modality of choice for hypercatabolic AKI
associated with sepsis. Main CRRT complications were
access and circuit clotting. The patients’ conditions and
modality choices were quite different, with smaller patients
with more stable conditions receiving PD, while hemody-
namically unstable, somewhat larger, patients received
CRRT. These data support, in part, the conclusions reached
by Fleming et al. [82]. They retrospectively compared PD
(n=21) and CRRT (n=21) in 42 children following repair
of congenital heart disease lesions. The common indica-
tions for RRT implementation included fluid overload,
electrolyte abnormalities, provision of total parenteral
nutrition (TPN), and oliguria. No standardized initiation
criteria were utilized, and this varied significantly among
patients. Additionally, nine patients in the CRRT group
received arteriovenous CRRT. Most of the patients (90%)
required pressor support. While there was no difference
noted in terms of mortality rate between modalities (62%
for both), CRRT was superior to PD for ultrafiltration,
solute clearance and nutritional provision. From these data,
the authors concluded that CRRT was superior to PD in this
clinical setting. The conclusions of their study must be
guarded, as patient care was not standardized in terms of
modality initiation criterion. Also, the patient group was
rather homogeneous, making generalizability difficult, and
no apparent survival benefit was noted with improved
solute and ultrafiltration in the CRRT group. Bunchman et
al. [75] reviewed survival outcome in 226 pediatric patients
receiving various forms of RRT, including PD, IHD and
CRRT, over a 7-year period from 1992–1998. Patients were
treated with CRRT (n=106), IHD (n=61) or PD (n=59).
Factors influencing patient survival included: (1) low blood
pressure (BP) at the initiation of RRT (33% survival, low
BP; 61%, normal BP; 100%, high BP; P<0.05); (2) pressor
use anytime during RRT (35% survival on pressors; 89%
survival not requiring pressors; P<0.01); (3) diagnosis
(improved outcome in those with primary renal failure
compared to those with secondary renal failure; P<0.05);
(4) RRT modality (40% survival, CRRT; 49% survival, PD;
81% survival, IHD; P<0.01 IHD vs PD or CRRT), and (5)
pressor support was significantly higher in children on
CRRT (74%) and PD (81%) vs IHD (33%) (P<0.05 IHD
vs CRRT or PD). The authors concluded that hemodynamic
support (sicker patients) with pressors imparted a greater
prediction of mortality, rather than RRT modality, and that
survival of children, as of adults, is best predicted by the
underlying diagnosis and hemodynamic stability. Interest-
ingly, modality choice was determined, in part, by patient
status. That is, patients with greater hemodynamic instabil-
ity were preferentially treated with PD or CRRT, and many
of these patients required pressor support.
Discussion
The data for RRT modality choice in the treatment of
pediatric AKI are clearly limited. As in many areas of
pediatrics, the majority of reports are retrospective, small,
non-randomized, single-center studies that reflect a homo-
geneous group of patients and have limited scope. Indeed,
many of these studies inherently reflect the practice stand-
ards of the institution and investigator bias. There are
several questions that clinicians must address when making
RRT modality decisions for treating pediatric AKI: “When
should we initiate dialysis or how aggressive should
volume and solute be controlled?”; “How severely ill is
the patient and what modality would best serve the patient’s
needs/limitations?”; “What modalities are available?”;
“What is the local expertise for delivering the modality?”
In order to address these questions we must develop
standard principles to allow comparative analysis of
pediatric patients with AKI. Foremost is the acceptance of
common criteria for the diagnosis of AKI. With the recent
validation of the pRIFLE criteria [6], we have a consensus
definition that could, for the first time, allow us to compare
data sets across institutions. This could revolutionize our
approaches to RRT modality choice and, indeed, guide
future randomized studies. While the indications for
dialysis are reasonably well understood, data regarding
when to intervene with RRT are limited. Through prospec-
tive multicenter analysis in pediatrics, the ppCRRT consor-
tium has nicely demonstrated a variety of important
variables in terms of treatment of pediatric AKI, including
fluid overload as an independent risk factor for mortality
[23, 67–71]. These data, along with data from adults [89],
suggest that early intervention is essential for the improve-
ment of outcomes in terms of CRRT. Indeed, earlier
intervention with PD in post-operative children with
congenital heart disease has also been proposed to have
survival advantages [90]. These data support the use of
early intervention prior to significant (>15% over body
weight) fluid overload [71–74]. In addition to these
variables, the particular role of “dosing of dialysis” has
become an increasingly important variable. “Dialysis dose”
disparity between CRRT, IHD and PD makes it difficult for
them to be compared adequately with each other in a
meaningful fashion. Indeed, even intra-modality variability
44 Pediatr Nephrol (2009) 24:37–48of dosing is the subject of investigation. Ronco et al. [89],
in their landmark randomized study of adults on CVVH,
demonstrated that an ultrafiltration prescription (dose) of
35 ml/kg per hour was superior to that of 20 ml/kg per hour
in terms of overall patient survival. Furthermore, subgroup
analysis revealed that patients with sepsis benefited when
higher ultrafiltration rates (45 ml/kg per hour) were utilized.
No such dosing studies have been performed in pediatric
patients, and most centers have used a rate of 2,000 ml/
1.73 m
2 body surface area per hour (an extrapolation based
on IHD), with a minimum rate of 35 ml/kg per minute.
Also evident in the literature review is the necessity of
use of a severity of illness score when a patient’s clinical
status is being evaluated. Clearly, false conclusions can be
made if sicker patients are included in one modality vs
another. This has been demonstrated by Swartz et al. [84,
91] in two analyses. In the first [91], 350 adult patients with
AKI were treated with either IHD or CRRT. This
retrospective analysis suggested that patients treated with
CRRT had poorer outcomes; however, when multivariate
analysis was used to control for severity of illness, CRRT
and IHD appeared to have equivalent outcomes. In the
second [84], more recent, study of 222 patients from the
same center, it appeared that, when severity of illness was
controlled for, CRRT was superior to IHD in terms of
patient survival. Pediatric studies have also demonstrated
the necessity for adaptation of severity of illness scores
for the adequate comparison of RRT modality efficiencies
[92, 93].
In centers with limited resources, the onus is on
optimizing and implementing available care, as was nicely
outlined by Phadke and Dinaker [50] and Ronco [94]. With
further clarification of variables affecting outcome in
pediatric AKI, the mortality rate should be affected in a
positive fashion. The epidemiology and technical expertise
available for treatment of pediatric AKI will continue to
evolve. In order to serve the pediatric population better, the
clinician’s responsibility is to utilize the literature and
updated developments to guide our choices. Indeed,
practice standards for AKI RRT management have been
proposed in Europe, based on available data and consensus
[79]. The challenge facing the pediatric nephrology and
intensivist community in developed countries is to carry out
multi-center, randomized, controlled trials comparing
patients with similar stages of AKI stratified to the various
RRT modalities. We have come close to being able to carry
out such studies with the availability of tools such as the
pRIFLE criteria, severity of illness scores, and identifiable
important variables (i.e. fluid overload). In addition to these
important developments, the ongoing identification and
predictive validation of AKI biomarkers [95–99] in terms
of onset, course and prognosis of pediatric AKI makes the
coming years very exciting.
Questions
(Answers appear after the reference list)
1. The use of temporary peritoneal dialysis would be the
last choice in terms of provision of renal replacement
therapy in a patient with acute kidney injury in which
setting?
a. A 4-year-old patient with E. coli-associated hemo-
lytic uremic syndrome, with mild gastrointestinal
symptoms and anuric acute kidney injury
b. A 14-year-old girl with mild (<5% over body
weight) fluid overload, no pulmonary edema
and a diagnosis of post-infectious glomerulone-
phritis with associated oliguria and acute kidney
injury
c. A neonate which a status of post-operative repair of
a ventricular septal defect (VSD) with hemody-
namic instability, anuria and associated acute
kidney injury presumed to be from acute tubular
necrosis
d. A neonate with hyperammonemia secondary to an
inborn error of metabolism presenting with acute
kidney injury and dehydration
2. CRRT as a therapy offers which benefits over short-
term PD?
a. It is widely available in developed and developing
countries
b.) It is technically easier to perform
c. It allows more accuracy in ultrafiltration and better
solute clearance
d. Anticoagulation is not required
3. From the following dialytic indications, which would
most fit with the choice of CRRT over PD in the setting
of AKI? Choose all that apply.
a. Severe fluid overload (approximately 20% over
base weight), pulmonary edema, hemodynamic
instability, hyperphosphatemia and hyperkalemia
b. Neonate status post-operative. Left hypoplastic
heart repair with compromised vasculature, hemo-
dynamic instability, nominal fluid balance, normal
electrolyte levels
c. A 16-year-old male trauma victim (automobile acci-
dent) with significant crush injury (myoglobinemia,
hyperkalemia and hyperphosphatemia), status post-
splenectomy
d. A bone marrow transplant (BMT) patient with
sepsis and early fluid overload (10% over base
weight) with hemodynamic instability, normal
metabolic profile, anuria and the initial phases of
pulmonary edema (not intubated yet).
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include which measures? Choose all that apply.
a. Control of fluid balance
b. No significant change in dietary intake
c. Blood pressure control
d. Improvement of survival
5. When considering dialysate solutions for either acute
PD or CRRT in the setting of AKI, which of the
following statements are true?
a. Pharmacy-prepared solutions are always the best
options for provision of dialysate for both PD and
CRRT
b. Commercially available, government regulatory
body-approved dialysate solutions are available
for both PD and CRRT
c. Lactate-based dialysate solutions are optimal for all
patients when either PD or CRRT is used
d. Under special patient circumstances, custom-made
solutions may be appropriate for patients receiving
either PD or CRRT
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